Minerva Neurosciences, Inc. reported its third quarter 2025 financial results and business updates. The company announced it has secured $80 million in gross proceeds from a private placement completed on October 23, 2025, with the potential to receive up to an additional $120 million if certain warrants are exercised and clinical milestones are achieved. Minerva Neurosciences stated that, following recent financing and alignment with the FDA on a confirmatory Phase 3 clinical trial, it is advancing roluperidone for the treatment of negative symptoms of schizophrenia and preparing for a potential commercial launch in the US, if approved. For the quarter ended September 30, 2025, research and development (R&D) expenses were $0.9 million, down from $1.9 million in the same period in 2024. For the nine months ended September 30, 2025, R&D expenses totaled $3.6 million, compared to $9.9 million in the prior year period. The decrease in R&D expenses was attributed to lower costs related to the drug substance validation campaign, consultant fees, and compensation expenses.